MedTrace Logo

Efficacy Study of Canakinumab to Treat Urticaria

NCT01635127 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-09-27

No results posted yet for this study

Summary

Evaluation whether canakinumab leads to improvement of urticaria

Conditions

  • Chronic Idiopathic Urticaria

Interventions

DRUG

Canakinumab

150mg s.c.

DRUG

Placebo

Constituent of canakinumab

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Peter Schmid-Grendelmeier, Prof MD · University Hospital Zurich, Division of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2016-12-31
Completion
2017-05-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01635127 on ClinicalTrials.gov